Evidence map›Paper›PMID 39106160›Full record

ArticleNucleic acids research2024

Central role of SUMOylation in the regulation of chromatin interactions and transcriptional outputs of the androgen receptor in prostate cancer cells.

Kaisa-Mari Launonen, Vera Varis, Niina Aaltonen, Einari A Niskanen, Markku Varjosalo, Ville Paakinaho, Jorma J Palvimo

Abstract read
In one paragraph

Article in Nucleic acids research, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 11 papers.

0numbers the graph read from it
0cells of the map it votes in
11citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

11 citing papers in PubMed.

  1. Review
  2. Regulation of lineage reprogramming by dynamic chromatin SUMOylation.Cellular and molecular life sciences : CMLS · 2026
    Article
  3. Article
  4. Article
  5. Article
  6. Article
  7. Review
  8. Article
  9. Article
  10. Article
  11. The impact of dysregulation SUMOylation on prostate cancer.Journal of translational medicine · 2025
    Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors.

Kaisa-Mari LaunonenInstitute of Biomedicine, Faculty of Health Sciences, University of Eastern Finland, Kuopio, Finland.
Vera VarisInstitute of Biomedicine, Faculty of Health Sciences, University of Eastern Finland, Kuopio, Finland.
Niina AaltonenInstitute of Biomedicine, Faculty of Health Sciences, University of Eastern Finland, Kuopio, Finland.
Einari A NiskanenInstitute of Biomedicine, Faculty of Health Sciences, University of Eastern Finland, Kuopio, Finland.ORCID 0000-0001-9471-7026
Markku VarjosaloInstitute of Biotechnology, HiLIFE, University of Helsinki, Helsinki, Finland.ORCID 0000-0002-1340-9732
Ville PaakinahoInstitute of Biomedicine, Faculty of Health Sciences, University of Eastern Finland, Kuopio, Finland.ORCID 0000-0003-4204-1436
Jorma J PalvimoInstitute of Biomedicine, Faculty of Health Sciences, University of Eastern Finland, Kuopio, Finland.ORCID 0000-0003-2373-0578

Funding

Cancer Foundation Finland 62-5909Finnish Cultural Foundation 00220596Paavo Koistinen foundation 202000004Research Council of Finland 333866Sigrid Jusélius FoundationUEF Doctoral Program of Molecular Medicine
6 · The paper itself

Abstract

The androgen receptor (AR) is pivotal in prostate cancer (PCa) progression and represents a critical therapeutic target. AR-mediated gene regulation involves intricate interactions with nuclear proteins, with many mediating and undergoing post-translational modifications that present alternative therapeutic avenues. Through chromatin proteomics in PCa cells, we identified SUMO ligases together with nuclear receptor coregulators and pioneer transcription factors within the AR's protein network. Intriguingly, this network displayed a significant association with SUMO2/3. To elucidate the influence of SUMOylation on AR chromatin interactions and subsequent gene regulation, we inhibited SUMOylation using ML-792 (SUMOi). While androgens generally facilitated the co-occupancy of SUMO2/3 and AR on chromatin, SUMOi induced divergent effects dependent on the type of AR-binding site (ARB). SUMOi augmented AR's pioneer-like binding on inaccessible chromatin regions abundant in androgen response elements (AREs) and diminished its interaction with accessible chromatin regions sparse in AREs yet rich in pioneer transcription factor motifs. The SUMOi-impacted ARBs divergently influenced AR-regulated genes; those associated with AR-mediated activation played roles in negative regulation of cell proliferation, while those with AR-mediated repression were involved in pattern formation. In conclusion, our findings underscore the pervasive influence of SUMOylation in shaping AR's role in PCa cells, potentially unveiling new therapeutic strategies.

Indexed as

ChromatinGene Expression Regulation, NeoplasticProstatic NeoplasmsReceptors, AndrogenSmall Ubiquitin-Related Modifier ProteinsSumoylationBinding SitesCell Line, TumorHumansMaleProtein BindingTranscription, GeneticUbiquitinsAR protein, humanChromatinReceptors, AndrogenSmall Ubiquitin-Related Modifier ProteinsSUMO2 protein, humanSUMO3 protein, humanUbiquitins

Identifiers

PMID39106160
PMCPMC11381344

What Socratic holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.